Drugs / incomplete Freund's adjuvant
incomplete Freund's adjuvant
also known as
Montanide ISA-51 · Montanide ISA 51 VG · Montanide · Montanide(R) ISA-51 · VEGFR1-A24-1084
Trials 12 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 107 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT01748747 Background | Oct 2012 → Dec 2014 | melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT00640861 Background | Aug 2008 → Apr 2015 | female breast carcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT00091286 Background | Mar 2003 → Feb 2008 | colorectal cancer | Craig L Slingluff, Jr | Terminated | No outcome recorded |
| Phase 132 trials | ||||||
| Phase 1 | NCT06789198 Background | Jul 2025 → Nov 2028 expected | fibrolamellar hepatocellular carcinoma | University Hospital Tuebingen | Recruiting | No outcome recorded |
| Phase 1 | NCT05937295 Background | Sep 2023 → Sep 2026 expected | fibrolamellar hepatocellular carcinoma | University Hospital Tuebingen | Recruiting | No outcome recorded |
| Phase 1 | NCT06218511 Background | Nov 2022 → Aug 2025 overdue | hepatocellular carcinoma | National Cancer Institute, Naples | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04978727 Background | Jul 2022 → Dec 2027 expected | anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, diffuse intrinsic pontine glioma +3 | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03879694 Background | Jun 2019 → Feb 2025 | atypical carcinoid tumor, lung carcinoid tumor, pancreatic neuroendocrine tumor | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT03299309 Background | Jun 2018 → Apr 2023 overdue | brain cancer, malignant glioma, medulloblastoma | Daniel Landi | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02334865 Background | Apr 2017 → Sep 2022 overdue | plasma cell myeloma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02526316 Background | Jun 2015 → May 2017 | virus associated tumor | Oryx GmbH & Co. KG | Completed | No outcome recorded |
| Phase 1 | NCT01810016 Background | Jan 2014 → May 2016 | metastatic melanoma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
| Phase 1 | NCT01390064 Background | Jul 2011 → Jul 2018 | breast cancer | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT01176461 Background | Aug 2010 → Dec 2016 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01259505 Background | Dec 2009 → Jun 2012 | breast cancer | Tokyo Medical University | Completed | No outcome recorded |
| Phase 1 | NCT00972309 Background | May 2009 → Feb 2015 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01673217 Background | Apr 2009 → Oct 2011 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00821652 Background | Feb 2009 → Jan 2010 | neoplasm | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 1 | NCT00753844 Background | Nov 2006 → Jun 2009 | esophageal cancer | Kinki University | Completed | No outcome recorded |
| Phase 1 | NCT00398138 Background | Oct 2006 → Jun 2009 | leukemia, lung cancer, malignant mesothelioma, myelodysplastic syndrome +1 | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00381875 Background | Jul 2006 → Feb 2011 | — | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT00299728 Background | Mar → Oct 2006 | neoplasm | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT00295581 Background | Mar 2005 → Jun 2008 | Plasmodium falciparum malaria, Plasmodium vivax malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00118313 Background | Nov 2004 → Jul 2006 | cutaneous melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1 | NCT00559026 Comparator | Sep 2004 → Sep 2006 | melanoma | Italian National Institute of Health | Completed | No outcome recorded |
| Phase 1 | NCT00091338 Background | Aug 2004 → ? | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00091143 Background | Jul 2004 → Mar 2010 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00091104 Background | Jul 2004 → Aug 2010 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT00091273 Background | Jun 2004 → Feb 2006 | ovarian cancer, primary peritoneal carcinoma | University of Virginia | Completed | No outcome recorded |
| Phase 1 | NCT00079157 Background | Feb 2004 → Dec 2007 | breast cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00199836 Background | Sep 2003 → Sep 2005 | cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT00112229 Background | Apr 2003 → Aug 2011 | melanoma | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT00025181 Background | Oct 2001 → Jan 2003 | cutaneous melanoma, ocular melanoma | University of Southern California | Completed | No outcome recorded |
| Phase 1 | NCT00020267 Background | Jul 2000 → ? | bone cancer, breast cancer, colon carcinoma, lung cancer +5 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00005841 Background | Jun → Dec 2000 | cutaneous melanoma, ocular melanoma | University of Southern California | Terminated | No outcome recorded |
| Phase 1/217 trials | ||||||
| Phase 1/2 | NCT05898763 Background | Sep 2021 → Apr 2024 | non-small cell lung carcinoma | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02938442 Background | Jan 2019 → Jan 2023 | triple-negative breast carcinoma | University of Arkansas | Completed | No outcome recorded |
| Phase 1/2 | NCT02264236 Background | Oct 2015 → Jun 2021 | lung neoplasm | University of Arkansas | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02425306 Background | May 2015 → Aug 2017 | melanoma | Craig L Slingluff, Jr | Terminated | No outcome recorded |
| Phase 1/2 | NCT02229084 Background | Jan 2015 → Jan 2023 | breast cancer | University of Arkansas | Completed | No outcome recorded |
| Phase 1/2 | NCT01950156 Background | Sep 2011 → Mar 2019 | non-small cell lung carcinoma | Shiga University | Completed | No outcome recorded |
| Phase 1/2 | NCT01462838 Background | Aug 2011 → Jan 2015 | virus associated tumor | Oryx GmbH & Co. KG | Completed | No outcome recorded |
| Phase 1/2 | NCT01312389 Background | Apr 2011 → May 2012 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded |
| Phase 1/2 | NCT01308294 Background | Jun 2010 → Apr 2014 | melanoma | Centre Hospitalier Universitaire Vaudois | Terminated | No outcome recorded |
| Phase 1/2 | NCT00678509 Background | May 2008 → Mar 2009 | breast cancer | Tokyo University | Terminated | No outcome recorded |
| Phase 1/2 | NCT00681421 Background | May 2008 → Apr 2009 | esophageal cancer | Tokyo University | Completed | No outcome recorded |
| Phase 1/2 | NCT02429440 Comparator | May 2005 → Oct 2017 | renal cell carcinoma | University Hospital Tuebingen | Unknown | No outcome recorded |
| Phase 1/2 | NCT00118274 Background | Mar 2005 → Feb 2010 | cutaneous melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1/2 | NCT02452307 Background | Apr 2004 → Oct 2017 | prostate carcinoma | University Hospital Tuebingen | Unknown | No outcome recorded |
| Phase 1/2 | NCT00062036 Background | Jun 2003 → Feb 2007 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1/2 | NCT00004918 Background | Dec 1999 → Dec 2007 | acute myeloid leukemia, leukemia, myeloid, accelerated-phase, myelodysplastic syndrome with excess blasts, refractory anemia with excess blasts in transformation | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00005629 Background | Jul 1999 → May 2002 | liver cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 250 trials | ||||||
| Phase 2 | NCT05479045 Background | Sep 2026 → Nov 2027 expected | ovarian carcinoma, uterine adnexa cancer | Georgetown University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06202066 Background | Jul 2026 → Oct 2027 expected | cancer, lung neuroendocrine neoplasm, pancreatic neuroendocrine neoplasm | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07169617 Background | Jul 2026 → Mar 2029 expected | lung carcinoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03003195 Background | Mar 2021 | metastatic malignant neoplasm | University of Arkansas | Withdrawn | No outcome recorded |
| Phase 2 | NCT04013672 Background | Mar 2020 → Aug 2021 | glioblastoma | David Peereboom | Completed | No outcome recorded |
| Phase 2 | NCT03946358 Background | Feb 2020 → Mar 2024 | anal canal cancer, cervical cancer, head and neck squamous cell carcinoma | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 2 | NCT03939234 Background | Apr 2019 → Mar 2021 | B-cell chronic lymphocytic leukemia | Lars Møller Pedersen | Completed | No outcome recorded |
| Phase 2 | NCT03850522 Background | Feb 2019 → Mar 2021 | smoldering plasma cell myeloma | Lene Meldgaard Knudsen | Terminated | No outcome recorded |
| Phase 2 | NCT03180801 Background | Aug 2016 → Mar 2017 | influenza | PepTcell Limited | Completed | No outcome recorded |
| Phase 2 | NCT02455557 Background | May 2015 → Oct 2019 overdue | gliosarcoma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00923195 Background | Dec 2008 → Aug 2011 | melanoma, skin cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00706992 Background | Jun 2008 → Nov 2012 | melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00513578 Background | Jan 2007 → Jan 2009 | myelodysplastic syndrome | The Vaccine Company | Unknown | No outcome recorded |
| Phase 2 | NCT00357461 Background | May 2006 → ? | cutaneous melanoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 2 | NCT00295958 Background | Dec 2005 → Jun 2006 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT00303836 Background | Nov 2005 → Jan 2007 | metastatic melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00428077 Background | Oct 2005 → Apr 2009 | leukemia | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00071981 Background | May 2005 → Aug 2011 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00109811 Background | Mar 2005 → Sep 2007 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00104780 Background | Dec 2004 → ? | lung cancer | Epimmune | Unknown | No outcome recorded |
| Phase 2 | NCT00089063 Background | Jun 2004 → Jun 2007 | iris melanoma, medium/large size posterior uveal melanoma, ocular melanoma with extraocular extension | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00184067 Background | May 2004 → Apr 2007 | melanoma | University of Southern California | Terminated | No outcome recorded |
| Phase 2 | NCT00077532 Background | Mar 2004 → Jan 2007 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT00080353 Background | Mar 2004 → Dec 2007 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00079144 Background | Jan 2004 → Aug 2005 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00089193 Background | Sep 2003 → Feb 2007 | cutaneous melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 2 | NCT00072085 Background | Sep 2003 → Jul 2006 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00059475 Background | Apr 2003 → May 2010 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00089206 Background | Aug 2002 → Nov 2005 | cutaneous melanoma, ocular melanoma | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT00031733 Background | Feb 2002 → Dec 2004 | cutaneous melanoma, ocular melanoma | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT00032045 Background | Jan 2002 → Aug 2006 | cutaneous melanoma, ocular melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00022438 Background | Jun 2001 → Aug 2004 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00021164 Background | May 2001 → May 2004 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00020475 Background | Feb 2001 → Mar 2007 | ocular melanoma with extraocular extension | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00006385 Background | Sep 2000 → Oct 2006 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00020358 Background | Sep 2000 → Oct 2007 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00030602 Background | Jan 2000 → Dec 2001 | prostate cancer | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 2 | NCT00019994 Background | Oct 1999 → Oct 2007 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00001832 Background | Aug 1999 → May 2010 | melanoma, metastatic neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00001827 Background | Jul 1999 → Dec 2007 | ovarian neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00019721 Background | Apr 1999 → Jun 2003 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00019487 Background | Nov 1998 → May 2003 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00003568 Background | Nov 1998 → Dec 2005 | cutaneous melanoma | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00003339 Background | Nov 1998 → Nov 1999 | cutaneous melanoma, ocular melanoma | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT00001703 Background | Aug 1998 → Nov 2008 | renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00003362 Background | May 1998 → Feb 2001 | cutaneous melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003222 Background | Apr 1998 → Sep 2003 | cutaneous melanoma | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT00003274 Background | Mar 1998 → Sep 2001 | cutaneous melanoma | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT00019396 Background | Feb 1998 → Mar 2007 | melanoma, renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00019383 Background | Jan 1998 → Jun 2003 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00019682 Background | Dec 1999 → May 2011 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05876195 Comparator | Mar → Oct 2023 | — | University of Oxford | Unknown | No outcome recorded |
| — | NCT00912574 Comparator | Jun 2004 → Jul 2008 | melanoma | University of Virginia | Completed | No outcome recorded |
| — | NCT00006243 Background | Oct 2000 → May 2006 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05014607 Background | — | cancer | University Hospital Tuebingen | Available | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 121 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | incomplete Freund's adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00513578 ↗50 |
| Known as | Montanide | “Montanide ISA-51 (Incomplete Freund's Adjuvant)” PMID 26500235 ↗ Oct 2015 |
| Known as | Montanide ISA 51 VG | “Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific...” NCT00428077 ↗25“NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3...” NCT01810016 ↗ “Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF).” NCT00972309 ↗ “Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant” NCT05014607 ↗ “P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG "Chemotherapy" Subcutaneous injection” NCT02264236 ↗ “the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).” NCT05937295 ↗ “NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG” NCT00299728 ↗ “P16_37-63 peptide combined with Montanide® ISA-51 VG” NCT02526316 ↗ “P10s-PADRE/MONTANIDE ISA 51 VG vaccine” NCT03003195 ↗ “mixed with 0.3 ml Montanide ISA-51 VG” NCT01462838 ↗ “Montanide ISA 51 VG (1:1)” NCT06789198 ↗ |
| Known as | Montanide ISA-51 | “Arm 1, vaccine alone: patients received i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c....” NCT00559026 ↗43“Participants were randomly assigned (1:1:1), using block randomisation and a computer-generated randomisation sequence, to treatment with either 200 nmol of AGS-v vaccine...” PMID 32534628 ↗ Jun 2020 “PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.” NCT03850522 ↗ “Montanide ISA™ 51 is a water-in-oil (W/O) emulsion composed of a mineral oil and a surfactant from the mannide monooleate family with immune stimulatory effect .” NCT06218511 ↗ “CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.” NCT01259505 ↗ “PEP-CMV Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.” NCT03299309 ↗ “URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.” NCT00681421 ↗ “Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51” NCT03180801 ↗ “Patients receive carcinoembryonic antigen peptide 1-6D (CAP 1-6D) emulsified in Montanide ISA-51 adjuvant subcutaneously on day 1.” NCT00012246 ↗ “100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant.” NCT05479045 ↗ “On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection” NCT00753844 ↗ “The vaccines also contain a substance called Montanide ISA51, which boosts the immune response to the vaccine.” NCT00295581 ↗ “vaccine comprising multiple synthetic melanoma peptides, sargramostim (GM-CSF), and Montanide ISA-51” NCT00089206 ↗ “HLA-A\*2402 restricted epitope peptides URLC10, CDCA1, and KIF20A emulsified with Montanide ISA 51” NCT01950156 ↗ “Montanide ISA-51, an incomplete Freund's adjuvant (IFA), is used in many vaccine trials” PMID 32350119 ↗ Apr 2020 “first, CpG 7909 oligodeoxynucleotides, and second, Montanide ISA-51.” NCT00112229 ↗ “SurVaxM will be mixed with Montanide ISA 51 before it is given.” NCT04978727 ↗ “UCPVax (combined with Montanide ISA51 as adjuvant)” NCT03946358 ↗ “Montanide ISA-51 (Incomplete Freund's Adjuvant)” PMID 26500235 ↗ Oct 2015 “emulsified in 2 ml of Montanide ISA-51” NCT00005629 ↗ |
| Known as | Montanide(R) ISA-51 | “a synthetic CpG 7909 ODN (deoxycytidyl-deoxyguanosin oligodeoxy-nucleotides) mixed with NY-ESO-1 peptide p157-165 and incomplete Freund's adjuvants (Montanide(R) ISA-51) led to...” PMID 19728336 ↗ Feb 2010 |
| Known as | VEGFR1-A24-1084 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00683358 ↗ |
| Modality | Other / unclassified | “incomplete Freund's adjuvant” NCT00003339 ↗ |
| Route | Subcutaneous | “injected subcutaneously every four weeks” NCT00001703 ↗ |